Journal: Cell

Article Title: Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity

doi: 10.1016/j.cell.2022.03.018

Figure Lengend Snippet: Study cohort characteristics

Article Snippet: To investigate how prior SARS-CoV-2 infection impacts the quantity and quality of vaccine-induced SARS-CoV-2-specific immune memory, we collected plasma and peripheral blood mononuclear cells (PBMCs) from 24 SARS-CoV-2 N and 30 SARS-CoV-2 PI individuals before vaccination and 1 week, 3 months, and 6 months after two vaccinations with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccines ( A; ; ; ).

Techniques: Infection

Journal: Advances in Therapy

Article Title: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

doi: 10.1007/s12325-022-02206-1

Figure Lengend Snippet: Antibody persistence 3 and 6 months after the first dose of BNT162b1 vaccination

Article Snippet: This study further extends our understanding of immune persistence and the safety of the BNT162b1 vaccine as a candidate vaccine in the BioNTech pipeline.

Techniques: Virus

Journal: Advances in Therapy

Article Title: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

doi: 10.1007/s12325-022-02206-1

Figure Lengend Snippet: Longitudinal geometric mean titer of virus-neutralizing antibody, anti-S1 IgG and anti-RBD IgG in healthy participants over 6 months. A GMT of neutralizing SARS-CoV-2 antibodies. B GMT of anti-S1 antibodies. C GMT of anti-RBD antibodies. Participants received two doses of BNT162b1 (10 or 30 µg) or placebo (saline) on days 1 and 22. Blood samples were not collected from older participants (aged 65–85 years) at day 8 and 3 months after dose 1. The error bar was standard error. anti-RBD IgG antibody to receptor binding domain, anti-S1 IgG antibody to S1 protein, GMT geometric mean titer, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2

Article Snippet: This study further extends our understanding of immune persistence and the safety of the BNT162b1 vaccine as a candidate vaccine in the BioNTech pipeline.

Techniques: Virus, Saline, Binding Assay

Journal: Advances in Therapy

Article Title: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

doi: 10.1007/s12325-022-02206-1

Figure Lengend Snippet:

Article Snippet: This study further extends our understanding of immune persistence and the safety of the BNT162b1 vaccine as a candidate vaccine in the BioNTech pipeline.

Techniques: Transmission Assay, Formulation, Generated

Journal: European Heart Journal: Case Reports

Article Title: Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease 2019 messenger RNA vaccines: a case report

doi: 10.1093/ehjcr/ytad063

Figure Lengend Snippet:

Article Snippet: A 59-year-old male with no medical history complained of chest pain a day after receiving the first dose of COVID-19 mRNA (BNT162b2) vaccination (Comirnaty, BioNTech/Pfizer) and was admitted to an affiliated hospital 3 days after this vaccination.

Techniques: Magnetic Resonance Imaging

Journal: F1000Research

Article Title: Tolerability of COVID-19 mRNA vaccines in patients with postural tachycardia syndrome: a cross-sectional study

doi: 10.12688/f1000research.109373.1

Figure Lengend Snippet: Effect of mRNA vaccination on POTS symptoms.

Article Snippet: The present study investigated the frequencies of known side effects of mRNA vaccination (Spikevax ® , Moderna; BNT162b2 ® , Pfizer) in patients with POTS.

Techniques: Concentration Assay